Novate Medical Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novate Medical Ltd.
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.
MedLumics appointed James Greene as its CEO and Giovanni Leo to the board of directors. The Madrid-based company expects the two industry veterans to carry it through the its next phase of growth – commercialization of the AblaView AF catheter.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.